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Materials and Methods:  
 
A previously developed survival model for stage III NSCLC, 
based on 548 patients, was tested on datasets from three 
different hospitals situated in the US (1), Belgium (2) and the 
Netherlands (3); 174, 130 and 112 patients, respectively. All 
patients were treated with high dose (chemo-) radiotherapy, 
but received no surgery. The C statistic was reported, Kaplan 
Meier (KM) curves were created for survival and Follow-up 
(FU) time. In addition, for all patients a linear predictor (LP) 
was computed by multiplying each variable with its 
regression coefficient and subsequently sum up the results. 
High LP-values indicate a worse prognosis according to the 
risk factors included in the model. The distributions of the 
LPs were compared graphically (Figure 1).  
Results: While the model achieved a C statistic of 0.63 in the 
development cohort (bootstrap), this decreased to 0.59, 0.56 
and 0.49, respectively, in the validation cohorts. Dataset 1 
included a more homogeneous population with a better 
prognosis according to the LP distribution, which was 
confirmed by the KM curve. Based on the LP distribution for 
dataset 2 and 3 it was expected that these cohorts had 
comparable but worse survival outcome than the 
development cohort. However, although the two-year overall 
survival was indeed similar being 44%, it was higher than that 
of the development cohort. The FU at two-years was 94% in 
the development cohort, while this was 59%, 89% and 51%, 
respectively, for the validation datasets, indicating major 
differences in either follow-up regimen or access to patient 
outcome data. 
Conclusions: A more extensive model validation reveals 
important information. To improve survival prediction for 
individual stage III NSCLC patients, more detailed information 
about patient populations and local policies, including 
specific diagnostic, treatment and follow-up procedures, is 
needed. An effort should be made to identify and collect 
these metadata electronically, applying a Big Data approach. 
Ultimately, this will enable us to develop more valid models 
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Purpose/Objective: To analyse the prognostic value of 
primary tumor FDG-response in serial PET/CTs during 
induction treatment with respect to overall survival. Relative 
SUV decrease is a known prognostic factor for histopathologic 
response after neoadjuvant RTCT in lung cancer. A 
confirmatory analysis of the prognostic value of relative SUV 
decrease was performed using outcome data from a 
randomized trial on definitive radiochemotherapy (RT/CT) 
compared with neoadjuvant RT/CT+surgery (trimodality). 
Materials and Methods: Pts with pathologically proven 
operable IIIA(N2) / selected IIIB NSCLC received 3 cycles 
cisplatin/paclitaxel and neoadjuvant chemoradiotherapy to 
45 Gy (1.5 Gy bid/ concurrent cisplatin/ vinorelbine). 
PET/CTs were recommended before initiation of induction 
treatment(time point t1), and before radiotherapy planning 
(9 weeks later, t2). Pts were reevaluated within an 
interdisciplinary panel during last week of RT/CT. Operable 
pts were randomized either to definitive RTCT (arm A: defRT 
to 65/71 Gy, concurrent cisplatin/vinorelbine) or surgery 
(arm B). SUVmax ratios (relSUVmax=SUVmax(t2)/SUVmax(t1)) 
were analysed as a continuous variable in proportional hazard 
analysis together with clinical pretreatment variables such as 
T and N categories, age, gender, and ECOG status, as well as 
treatment arm. 
Results: Between 1/2004 and 8/2012, 115 pts from a single 
centre were randomized in this trial. All had initial PET/CT 
investigations. From 105 patients (51 pts in arm A, 54 in arm 
B) SUVmax values from both time points (before treatment 
and before planning of the first radiotherapy series up to 45 
Gy) were available. In univariate and multivariable analysis 
of these 105 patients, relSUVmax was a significant prognostic 
factor for survival (p=0.019 and 0.015, respectively). In 
multivariable analysis, among all the above listed parameters 
relSUVmax turned out to be the strongest predictor of 
survival associated with a hazard ratio of death of 2.81 (1.23-
6.46). Treatment arm did not become significant. 5-year 
survival among patients with relSUVmax values in the upper 
quartile (>0.57) was 27% and for patients in the lowest 
quartile with relSUVmax <0.20 was 58%. Albeit the 
interaction effect between relSUVmax and treatment arm did 
not become significant, a larger hazard ratio of 3.58 (1.19-
10.76) was observed for relSUVmax in the defRT arm in 
comparison to the trimodality arm (HR=1.89 (0.62-5.72), 
n.s.). 
Conclusions: In this confirmatory study, relative SUVmax at 
the end of induction treatment turned out as a strong 
prognostic factor for survival in LAD-NSCLC especially after 
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definitive RT/CT. Further treatment intensification for 
patients with relative SUV >0.57 seems justified.  
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Purpose/Objective: 
Introduction: In literature a lower survival in a larger GTV 
was found in a retrospective analysis of a prospective 
database of 270 patients (Dehing-Oberije). These patients 
were treated with (chemo) radiotherapy for NSCLC. This 
raises the question to specify the GTV and the PTV further 
with a cutoff point in our own database with patients treated 
with CCRT for locally advanced NSCLC. 
Purpose: Is the GTV a better predictor of outcome of 
treatment (LC, LRC, DFS, OS) than the PTV? Can we find a 
cut-off with the inclusion of the volume prediction (GTV or 
PTV) to use the least toxic treatment with the same or better 
result for patients with locally advanced non-small cell lung 
carcinoma (NSCLC)? 
Materials and Methods: In 132 patients (PET-CT staged) 
treated with CCRT for locally advanced non-small cell lung 
carcinoma in the period 2005-2012, one observer delineated 
the GTV of the primary tumor and lymph nodes and the 
volume (cc) was calculated. The planning target volume 
(PTV) was generated, prognostic factors and outcome 
registered retrospectively. The Cox regression model and 
multivariate support will be calculated and the difference 
will be tested. The median volume (GTV and PTV) cutoff 
applied and tested separately for consistency in the spline 
predict model. 
Results: In the univariate analysis GTV (>77 cc) (p=0,031/HR 
1.9), PTV (>390 cc) (p=0.0035/HR 2,4) and gender 
(p<0,001/HR 0.3) are significantly favorable prognostic 
factors for overall survival (OS). In the multivariate cox-
regression analysis PTV >390 cc (p=0.012/HR 2,5) and gender 
(p=0,006/HR 0.35) (male: female) but not GTV are 
significantly favorable prognostic factors for OS. Age is in the 
univariate analysis (p=0.018/HR 0.96) and multivariate 
analysis (p=0.01/HR 0.95) the only significantly favorable 
prognostic factor for local relapse free survival.  
Conclusions: The GTV does not have a better prognostic 
value for overall survival and local recurrence free survival in 
patients with locally advanced NSCLC treated with CCRT than 
the PTV (Correlation factor =0.94). 
A cut off point for overall survival was found for GTV 77 cc 
and PTV 390 cc.  
Reference: 
Dehing-Oberije C, De Ruysscher D, van der Weide H, et al. 
Tumor volume combined with number of positive lymph node 
stations is a more important prognostic factor than TNM 
stage for survival of non-small-cell lung cancer patients 
treated with (chemo) radiotherapy. Int J Radiat Oncol Biol 
Phys 2008; 80(4): 1039-1044 
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Purpose/Objective: When formulating radiation treatment 
plans, it has long been assumed that tumor doses should be 
kept homogeneous throughout the tumor in order to 
maximize the likelihood of tumor control. This has lead to 
the widespread adoption of 'D95' as the standard plan-quality 
metric. However, the optimization of this parameter is often 
achieved at the expense of competing dose-volume metrics, 
putting the patient at increased risk of normal tissue 
toxicities despite scant clinical data to support the need for 
dose homogeneity, and mounting biological evidence against 
it. With this in mind, we set out to derive a novel, 
mechanistically-derived metric which accurately derives 
tumor control probabilities from each patient's unique dose 
distributions and fractionation schedules: 'generalized tumor 
dose' (gTD). 
Materials and Methods: The gTD metric was inspired by 
Niemierko's concept of gEUD, which applies a generalized-
mean term ('a') to the dose distribution over the structure of 
interest. Here we apply the same concept, however 
incorporating it into a dose-effect model mechanistically 
derived from known tumor radiobiology, and accounting for 
each patient's unique dosing, fractionation schedule, and 
tumor characteristics. In effect, the derived gTD metric 
reflects the level of absolute cell survival within the tumor, 
subject to the 'a'-based relative weighting of the high or low 
end of the dose distribution. Using parameter optimization 
methods on clinical lung tumor data from two institutional 
cohorts (NKI: N=266 & WUSTL: N=50), we tested the current 
assumption that outcome (local control/failure at last 
followup) is determined by the sum of independent dose 
effects to tumor sub-volumes. 
Results: 
 
Fitting model parameters to the combined cohort data using 
both log-likelihood and actuarial methods, we were able to 
